Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Russell NH. et al, (2025), J Clin Oncol, 43, 694 - 704

Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment.

Pinter J. et al, (2024), Syst Rev, 13

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.

Halik A. et al, (2024), J Hematol Oncol, 17

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.

Williams CJM. et al, (2024), J Clin Oncol

Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.

Braybrooke J. et al, (2024), Lancet, 403

Prognostic impact of CEBPA mutational subgroups in adult AML.

Georgi J-A. et al, (2024), Leukemia, 38, 281 - 290

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

Copland M. et al, (2023), Br J Haematol

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2023), Lancet, 402, 1991 - 2003

Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.

Taylor P. et al, (2023), J Clin Endocrinol Metab, 108, 2615 - 2625

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.

Hills RK., (2023), Br J Haematol

Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.

Freeman SD. et al, (2023), Blood

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.

Hills RK. et al, (2023), Journal of Clinical Oncology, 41, 508 - 508

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk None. and Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) None., (2023), Lancet, 401, 1277 - 1292

What drives CAR-T emergent cytopenia?

Hills RK., (2023), Br J Haematol

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.

Hills RK. et al, (2023), JOURNAL OF CLINICAL ONCOLOGY, 41

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.

Gray RG. et al, (2023), JOURNAL OF CLINICAL ONCOLOGY, 41

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

Othus M. et al, (2022), Leuk Lymphoma, 1 - 3

Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.

Love SB. et al, (2022), Trials, 23

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.

Bewicke-Copley F. et al, (2022), Blood Adv

Unified classification and risk-stratification in Acute Myeloid Leukemia.

Tazi Y. et al, (2022), Nat Commun, 13

Load More